| |
| |
|
| Insider
Information: |
Aselage Steve |
| Relationship: |
Director |
| City: |
Fremont |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
293,421 |
|
|
Indirect Shares
|
22,000 |
|
|
| Direct
Value |
$7,031,645 |
|
|
|
Indirect Value
|
$169,660 |
|
|
| Total
Shares |
315,421 |
|
|
| Total
Value |
$7,201,305 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
5
|
5
|
|
Stock
price went up :
|
1
|
3
|
| Stock
price went down : |
4
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
1.5
|
| Percentage
Gain/Loss : |
 -23.4%
|
 62.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Cti Biopharma Corporation |
CTIC |
EVP, Global Commercial... |
2005-06-30 |
24,133 |
2004-08-03 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Business Of... |
2012-07-02 |
59,030 |
2006-04-28 |
0 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
Director |
2022-05-11 |
146,919 |
2021-11-05 |
19,500 |
Premium* |
|
|
Acer Therapeutics Inc |
ACER |
Director |
2023-11-17 |
0 |
2017-09-19 |
0 |
Premium* |
|
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2024-05-24 |
63,339 |
2024-05-24 |
2,500 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
170 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CTIC |
Cti Biopharma Corporation |
EVP, Global Commercial Ops |
• – – |
2004-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
16,000 |
|
- |
|
| CTIC |
Cti Biopharma Corporation |
EVP Global Comm Operations |
• – – |
2004-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
30,000 |
|
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev. |
• – – |
2007-09-14 |
4 |
S |
$22.40 |
$224,000 |
D/D |
(10,000) |
4,895 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev. |
• – – |
2007-09-14 |
4 |
OE |
$7.16 |
$71,600 |
D/D |
10,000 |
14,895 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-03-02 |
4 |
S |
$21.00 |
$210,000 |
D/D |
(10,000) |
41,271 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-03-03 |
4 |
S |
$21.00 |
$210,000 |
D/D |
(10,000) |
31,271 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2011-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
41,478 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2012-05-15 |
4 |
OE |
$17.33 |
$173,300 |
D/D |
10,000 |
69,030 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2012-05-15 |
4 |
S |
$38.64 |
$386,373 |
D/D |
(10,000) |
59,030 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2020-06-25 |
4 |
AS |
$20.00 |
$200,000 |
D/D |
(10,000) |
238,732 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-03-17 |
4 |
OE |
$16.23 |
$162,300 |
D/D |
10,000 |
206,667 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-04-16 |
4 |
OE |
$16.23 |
$162,300 |
D/D |
10,000 |
198,940 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-04-16 |
4 |
AS |
$26.23 |
$262,300 |
D/D |
(10,000) |
188,940 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-11-05 |
4 |
AS |
$26.23 |
$262,300 |
D/D |
(10,000) |
161,794 |
0 |
% |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2021-11-05 |
4 |
OE |
$16.23 |
$162,300 |
D/D |
10,000 |
171,794 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2011-05-03 |
4 |
S |
$27.15 |
$279,895 |
D/D |
(10,311) |
31,478 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2011-05-03 |
4 |
OE |
$17.33 |
$178,690 |
D/D |
10,311 |
41,789 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Business Officer |
• – – |
2010-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
11,200 |
32,587 |
0 |
- |
|
| ACER |
Acer Therapeutics Inc |
|
• • – |
2017-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
11,905 |
11,905 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev |
• – – |
2009-05-12 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
45,916 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
• • – |
2018-08-31 |
4 |
AS |
$32.00 |
$384,000 |
D/D |
(12,000) |
245,883 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Chief Executive Officer |
• • – |
2018-08-31 |
4 |
OE |
$8.70 |
$104,400 |
D/D |
12,000 |
257,883 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Dev. |
• – – |
2008-05-06 |
4 |
OE |
$7.16 |
$142,348 |
D/D |
12,205 |
48,665 |
0 |
- |
|
| TVTX |
Travere Therapeutics, Inc |
Director |
– • – |
2020-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
12,250 |
260,716 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
SVP, Global Commercial Ops |
• – – |
2007-02-14 |
4 |
OE |
$7.16 |
$107,400 |
D/D |
15,000 |
17,829 |
0 |
- |
|
170 Records found
|
|
Page 5 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
